VCVitalii A. Cherniaev

Vitalii A. Cherniaev

*This is an algorithmically generated author record based on publicly available information.

Vitalii A. Cherniaev has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictive role of peripheral blood erythroblasts for treatment intensification in metastatic hormone-sensitive prostate cancer. A retrospective study

    by Olesia A. Stativko, Стативко Олеся Алексеевна, Irina A. Shangina, Шангина Ирина Александровна, Nikita M. Starostin, Старостин Никита Максимович, Ilya A. Pokataev, Покатаев Илья Анатольевич, Alexey A. Rumyantsev, Румянцев Алексей Александрович, et al.

    Aim. To investigate the predictive value of baseline erythroblasts in selecting patients with metastatic hormone-sensitive prostate cancer (mHSPC) for triplet therapy. Materials and methods. We provided a multicenter retrospective study that included patients treated between 2022 and 2024 for high-volume mHSPC according to CHAARTED criteria who received either doublet [androgen deprivation therapy (ADT) + an androgen receptor pathway inhibitor (ARPI)] or triplet (docetaxel + ADT + ARPI) therapy. The primary endpoint was 2-year progression-free survival (PFS), defined as time from treatment initiation to clinical or radiological progression, initiation of new systemic therapy, or death from any cause. Cardinality matching at a 2:1 ratio was performed to balance potential confounding variables. Results. A total of 234 patients were included (141 triplet, 93 doublet). After matching, 122 patients remained in the triplet group and 61 in the doublet group. With a median follow-up of 23.5 months for the triplet group and 33.9 months for the doublet group, 2-year PFS rates were 71.9 and 57.8%, respectively (HR 0.62, 95% CI 0.40–0.95; p=0.027). Subgroup analysis demonstrated significantly greater survival benefit from triplet therapy in patients with detectable baseline erythroblasts (PFS: HR 0.29, 95% CI 0.11–0.76; OS: HR 0.24, 95% CI 0.07–0.77) compared to those without erythroblasts (PFS: HR 0.66, 95% CI 0.37–1.19; OS: HR 0.52, 95% CI 0.26–1.06). Conclusion. The baseline presence of circulating erythroblasts serves as a strong predictive marker for benefit from docetaxel intensification in patients with high-volume mHSPC. This readily available biomarker may guide patient selection for triplet therapy, pending prospective validation.

  • Open Access

    Safety of four intravesical BCG therapy regimens in patients with non-muscle-invasive bladder cancer: second interim analysis of a phase II randomized trial

    by Maria I. Volkova, Yana V. Gridneva, Artur Sh. Baimashev, Ogulshat R. Sinitsyna, Albert V. Oskarev, Olesia A. Stativko, Ilya A. Pokataev, Elizaveta M. Koldakova, Vitalii А. Cherniaev, Georgy M. Mushukya, et al.

    Aim. To evaluate the safety of four regimens of Bacillus Calmette-Guérin (BCG) therapy following transurethral bladder resection in patients diagnosed with intermediate- and high-risk non-muscle-invasive bladder cancer. Materials and methods. This study is a prospective, interventional, four-arm, open-label, randomized phase II clinical trial with a non-inferiority design. The main inclusion criteria were histologically confirmed non-muscle-invasive bladder cancer of intermediate or high risk in patients aged 18 years or older who have undergone transurethral resection of the bladder. Participants were randomized into four treatment groups in a 1:1:1:1 ratio for intravesical therapy utilizing the BCG vaccine: test groups 1 (50 mg, 1 year), 2 (50 mg, 3 years), 3 (100 mg, 1 year), and a control group 4 (100 mg, 3 years). The primary endpoint of the randomized controlled trial was the one-year local recurrence rate, while secondary endpoints reported in this publication included safety and toxicity. Results. The second interim analysis, with a median follow-up of 16.7 months (range: 2.5–33.6 months), included data from 401 patients with a median age of 66.4 years (range: 31–95 years). Within the EORTC intermediate-risk group, 93 patients (23.2%) were included, while the high-risk group comprised 308 patients (76.8%). All patients received BCG therapy according to their assigned randomization group: group 1 – 100 patients (24.9%); group – 92 patients (23.0%); group 3 – 109 patients (27.2%); group 4 – 100 patients (24.9%). The treatment groups were balanced with respect to the main characteristics. A total of 133 patients (33.2%) and 184 patients (45.9%) required an adjustment in the interval between induction and maintenance instillations, respectively. The induction completion rate was 96.8%, while the maintenance administration rate was 86.0%. Adverse events (AEs) were reported in 363 patients (90.5%), with 40 events (10.0%) reaching grades 3–4, requiring hospitalization in 14 patients (3.5%). The most prevalent local AEs included dysuria (339 patients; 84.5%), hematuria (45 patients; 11.2%), and nonspecific urinary infection (42 patients; 10.5%). Systemic AEs included hyperthermia, affecting 85 patients (21.2%). Tuberculosis was diagnosed in 3 patients (0.7%). The analysis indicated no significant differences in the safety profile or toxicities among the study regimens when compared with the standard regimen. Conclusion. The findings from the second interim safety analysis do not support the hypothesis that the tolerability of the BCG regimen can be enhanced by reducing its intensity.

  • Open Access

    Impact of safety parameters and toxicity profile on the efficacy of first-line combination therapy in patients with advanced renal cell carcinoma: a real-world study

    by M. I. Volkova, T. A. Nersesova, M. A. Lyadova, Е. С. Кузьмина, T. G. Antonova, E. V. Tsareva, O. A. Stativko, V. A. Chernyaev, I. A. Pokataev

    Objective: To evaluate the impact of safety parameters and toxicity profile on the efficacy of first-line immuno-oncology (IO) — based therapy in patients with renal cell carcinoma (RCC) in real-world clinical practice. Materials and Methods: Inclusion criteria for this retrospective study were: age ≥ 18 years, histologically confirmed advanced RCC, and administration of first-line therapy with IO-based combination regimens. Exclusion criteria included contraindications to any combination therapy agents, lack of data on at least one administration of each combination agent, and absence of at least one follow-up examination after treatment initiation. All adverse events (AEs), their characteristics, and instances of treatment regimen modification due to AEs were documented, along with the best overall response to therapy, time to progression, time to death, and last follow-up. An analysis of the potential association between safety parameters and first-line therapy efficacy outcomes was performed. Results: Data from 194 patients were included, receiving either nivolumab with ipilimumab (IO — IO), 94 patients (48.5 %) or immuno-targeted therapy (IO — TKI) 100 patients (51.5 %). Median follow-up duration was 28.4 months (1–63 months). The objective response rate (ORR) in the entire population (IO — IO / TKI) was 36.6 %, disease control rate (DCR) was 79.4 %, median progression-free survival (PFS) was 20.0 months (95 % CI, 15.3–24.8), and median overall survival (OS) was 29.2 months (95 % CI, 24.4–34.0). In the IO — IO / TKI group, independent favorable prognostic factors for therapy efficacy were cutaneous AEs (risk ratio [RR] for ORR 5.9 [95 % confidence interval (CI): 3.1–38.4], p = 0.002; odds ratio [OR] for PFS 2.4 [95 % CI: 1.2–4.6], p = 0.011), endocrine AEs (RR for ORR 2.5 [95 % CI: 1.8–3.5], p = 0.021; OR for PFS 2.6 [95 % CI: 1.4–4.8], p = 0.002; OR for overall survival [OS] 2.6 [95 % CI: 1.5–4.6], p = 0.001), and gastrointestinal (GI) AEs (OR for PFS 1.8 [95 % CI: 1.1–3.2], p = 0.030). Independent unfavorable prognostic factors for OS were serious AEs (OR 24.9 [95 % CI: 4.7–130.5], p < 0.0001).Independent favorable prognostic factors in the IO — IO group were endocrine AEs (OR for PFS 2.1 [95 % CI: 1.1–4.1], p = 0.026; OR for OS 2.8 [95 % CI: 1.4–5.6], p = 0.003), while in the IO — TKI group, favorable prognostic factors included the occurrence of any AEs (OR for OS 2.9 [95 % CI: 1.1–7.5], p = 0.033), cutaneous AEs (RR for ORR 3.1 [95 % CI: 1.2–6.2], p = 0.04; OR for PFS 3.0 [95 % CI: 1.2–7.6], p = 0.021), GI AEs (OR for PFS 3.3 [95 % CI: 1.5–7.2], p = 0.002), and endocrine AEs (OR for PFS 3.3 [95 % CI: 1.6–6.7], p = 0.001). Conclusions: The development of AEs in patients with RCC is associated with improved efficacy outcomes of IO based combination therapy. The potential use of AEs as biomarkers of clinical benefit from IO-based combination therapy warrants confirmation in prospective studies.

  • Open Access

    Comparative analysis of efficacy and safety of combined immunotherapy and immune targeted therapy in the first-line treatment of advanced renal cell carcinoma: a real-world study

    by Ilya A. Pokataev, Olesya A. Stativko, Maria I. Volkova, Alina N. Fedorova, Elena V. Zueva, Mulaim R. Ibragimova, Elena V. Tsareva, Tatiana G. Antonova, Ogulshat R. Sinitsyna, Vitalii A. Cherniaev, et al.

    Aim. To compare of efficacy and safety of combined immune therapy (dual immune-oncology – IO combination therapies, IO-IO) and immune targeted therapy (ITT) in the first line treatment of patients with advanced renal cell carcinoma (RCC) treated in real world clinical practice. Materials and methods. The ambispective study enrolled patients with metastatic RCC aged ≥18 years, with measurable neoplastic lesions, who were treated with first-line IO-IO therapy or ITT. The primary endpoint was progression-free survival (PFS). Results. The study included data from 126 patients treated with IO-IO [46 (36.5%) patients of the IMDC intermediate and poor prognostic groups] or ITT [80 (63.5%) patients of all IMDC prognostic groups]. In a median follow-up of all patients of 16.1 (0.1–44.9) months, the median PFS was 16.1 (10.9–21.3) months, the median overall survival (OS) was not reached; one-year OS was 83.0%; the objective response rate on the first line of therapy was 44.4% with a complete response rate of 3.2%. The rate of tumor control was 88.1%. In the overall population, ITT versus IO-IO provided a significant benefit in terms of ORR (51.2% vs 32.6%; p=0.032), PFS (median 22.9 months vs 8.0 months; p=0.004) and one-year OS (87.5% vs 65.2%; p=0.042). In the IPTW population, multivariate analysis confirmed the independent prognostic significance of the treatment regimen for PFS (hazard ratio, 2.3; 95% confidence interval, 1.1–4.8; p=0.037) and OS (hazard ratio, 2.3; 95% confidence interval 1.1–4.8; p=0.037). No difference in the safety profile of IO-IO and ITT was identified. Conclusion. The results support the hypothesis that ITT is more effective than IO-IO in the first-line treatment of advanced RCC in patients of IMDC intermediate and poor prognostic groups.


  • Open Access

    Laparoscopic technologies in the treatment of retroperitoneal ganglioneuroma

    by D. V. Erygin, I. A. Sklyar, V. A. Chernyaev, E. A. Kulikova, S. Yu. Trishchenkov, V. N. Galkin

    Лапароскопические технологии в лечении ганглионевромы забрюшинного пространства

  • Open Access

    Is technically complicated partial nephrectomy justified in renal cell carcinoma patients with normal contralateral kidney?

    by M. I. Volkova, V. A. Ridin, V. A. Cherniayev, A. V. Klimov, K. M. Figurin, A. A. Kirichek, V. B. Matveev

    Objective: to compare the results of partial (PN) and radical nephrectomy (RN) in patients with renal parenchymal tumors with nephrometric PADUA index ≥8 and/or RENAL index ≥7 and functioning contralateral kidney.Materials and methods. Medical data of 114 consecutive patients with renal cell carcinoma (RCC) cT1–3aN0M0 and functioning contralateral kidney were included into the study: 57 (50.0 %) persons undergone PN for tumors with nephrometric PADUA index ≥8 and/or RENAL index ≥7 (the main group), and 57 (50.0 %) patients undergone RN (the control group). The groups were comparable with regards to demographic characteristics, nephrometric parameters, morphological tumor features, and baseline glomerular filtration rate (р 0.05 for all). Median follow-up – 52.0 ± 23.6 (9.1–138.5) months.Results. Technically complicated PNs were associated with an increase of median surgery time (by 39 min, р = 0.06), blood loss (by 319 ml, p within the groups. Chronic kidney disease (CKD) progression rate was significantly higher in RN than in PN group (40 % vs 31.6 % respectively, р = 0.050), including more frequent development of CKD stages III–IV (31.6 % vs 26.3 % respectively; р = 0.034). There was no difference of long-term survival between PN and RN groups, and that included survival results stratified according to gender, age, baseline CKD stage, PADUA and RENAL indexes. Five-year recurrence-free survival was 94.1 % vs 92.2 % (р = 0.223), cancer-specific survival – 92.3 % vs 90.8 % (р = 0.443), cardio-specific survival – 91.6 % vs 77.9 % (р = 0.549), overall survival – 89.8 % vs 70.7 % respectively (р = 0.858).Conclusion. PN is effective and safe method of treatment in patients with renal parenchymal tumors with PADUA index ≥8 and/or RENAL index ≥7 and functioning contralateral kidney, providing significant functional benefit without survival compromising when compared with RN.


  • Results of kidney resection in patients with renal cell cancer with a high nephrometric index

    by M.I. Volkova, Federal State Budgetary Institution «National Medical Research Center for Oncology named after N.N. Blokhin» of Ministry of Health of Russian Federation, V.A. Ridin, V.A. Chernyaev, A.V. Klimov, K.M. Figurin

    Резекция почки является общепризнанным стан дартом в лечении больных клинически локализо ванными опухолями почечной паренхимы. Со вершенствование операционной техники привело к накоплению опыта технич


  • Open Access

    Clinical case of lymphoma of the seminal vesicle

    by V. B. Matveev, V. A. Ridin, V. N. Sholokhov, V. M. Snitkin, V. A. Chernyaev, B. V. Bukharkin, M. S. Makhotina, S. N. Berdnikov, D. A. Khalikova

    The article presents a clinical case of seminal vesicle lymphoma in a 73-year-old man who was sent for examination at the N.N. Blokhin National Medical Research Center of Oncology with suspected prostate tumor.

  • Open Access

    The first experience of using obturator nerve block to prevent spasm of adductor muscles of the thigh during transurethral resection of bladder

    by I. A. Rychkov, R. V. Garyaev, V. B. Matveev, V. A. Chernyaev

    The objective is to study the possibility of using the obturator nerve block under the control of nerve stimulator to prevent the thigh adductor muscles spasm during transurethral resection of bladder tumor.Materials and methods. The prospective randomized study included data obtained during the surgical treatment of 50patients with lateral wall bladder tumor, which was subjected transurethral resection of the bladder. In the GA group (n = 25) was performed general anesthesia with use muscle relaxants, in the NS group (n = 25) spinal anesthesia was performed in combination with obturator nerve block by 10 ml of a 2 % solution of lidocaine under the control of nerve stimulation.Results. The thigh adductor muscles spasm was observed in 5 cases (25 %) in the GA group and in 3 cases (12 %) in the NS group (p = 0.702), this was the cause of bladder perforation in 1 (4 %) patient in the NS group. The incidence of arterial hypotension in the NS group was lower than in the GA group (0 % versus 32 %; p = 0.004), as well as the incidence of sinus bradycardia (12 % versus 48 %; p = 0.012). The time of being in operating room in the NS group was 45 minutes (40; 53) versus 60 minutes (50; 85) in the GA group (p = 0.006).Conclusion. The spinal anesthesia in combination with obturator nerve block under the control of nerve stimulation, as well as the general anesthesia with use muscle relaxants did not guarantee the absence of adductor muscles spasm during transurethral resection of the lateral wall bladder. The obturator nerve block under the control of nerve stimulation only can not be recommended to prevent perforation of the bladder wall in these interventions.


  • Open Access

    Safety of left renal vein ligation during circular resection of the inferior vena cava in right-side kidney carcinoma with tumor venous thrombosis

    by M. I. Volkova, V. A. Chernyaev, A. K. Begaliev, A. V. Klimov, V. B. Matveev

    Objective: to assess safety of left renal vein (LRV) ligation during circular resection of the inferior vena cava in right-side kidney carcinoma with tumor venous thrombosis.Materials and methods. We selected medical data of 63 renal cell carcinoma patients with tumor venous invasion undergone nephrectomy, thrombectomy, IVC resection with LRV ligation (Group 1; n = 29 (46.0 %)) or preservation of venous outflow from the contralateral kidney (Group 2; n = 34 (54.0 %)). Median age of study participants was 56.0 + 8.8 years (range: 32—72 years); a male to female ratio was 1:1.9. Such parameters as age, gender, median glomerular filtration rate (GFR), stages of chronic kidney disease (CKD), blood loss, and duration of surgery were comparable across the two groups (р 0.05 for all parameters). Median follow-up was 32.8 months (range: 1—226 months). Results. We observed no significant changes in median GFR in the late postoperative period compared to baseline among patients with ligated LRV (65.7 vs 71.2 mL/min/1.73 m2; р 0.05) and patients with preserved venous outflow from the contralateral kidney (60.6 vs 68.4 mL/min/1.73 m2; р0.5). Patients that underwent LRV ligation were less likely to have reduced GFR compared to those with normal contralateral renal venous outflow (34.5 % vs 44.1 %; p 0.05). However, participants with ligated LRV had CKD upstaging (from stage 0—I to stage I—II) more frequently than participants with preserved venous outflow (27.6 % vs 5.9 %; р = 0.022). None of the patients developed stage III CKD after LRV ligation.Conclusion. LRV ligation during circular resection of the IVC in right-side renal cell carcinoma patients with tumor venous thrombosis does not lead to a clinically significant decrease in long-term deterioration of renal function.